Drive Wealth Management LLC raised its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 10.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,232 shares of the company’s stock after acquiring an additional 400 shares during the quarter. Drive Wealth Management LLC’s holdings in AstraZeneca were worth $330,000 as of its most recent filing with the SEC.
Several other institutional investors also recently made changes to their positions in AZN. Massachusetts Wealth Management purchased a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $226,000. Retireful LLC acquired a new position in AstraZeneca during the second quarter worth $2,019,000. Ritholtz Wealth Management boosted its position in AstraZeneca by 12.7% during the second quarter. Ritholtz Wealth Management now owns 66,235 shares of the company’s stock worth $5,166,000 after purchasing an additional 7,478 shares in the last quarter. Waldron Private Wealth LLC acquired a new stake in AstraZeneca in the second quarter valued at $275,000. Finally, Summit Financial LLC purchased a new position in shares of AstraZeneca in the second quarter valued at $438,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca Trading Up 0.4 %
Shares of AstraZeneca stock opened at $87.62 on Monday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The business’s fifty day moving average is $80.81 and its two-hundred day moving average is $75.00. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The firm has a market cap of $271.67 billion, a PE ratio of 42.95, a P/E/G ratio of 1.65 and a beta of 0.47.
AstraZeneca Cuts Dividend
The business also recently declared a Semi-Annual dividend, which will be paid on Monday, September 9th. Shareholders of record on Friday, August 9th will be issued a $0.49 dividend. The ex-dividend date of this dividend is Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%.
Wall Street Analysts Forecast Growth
AZN has been the topic of several recent research reports. TD Cowen boosted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. The Goldman Sachs Group began coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price objective for the company. Barclays raised AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Finally, Argus boosted their price target on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Buy” and a consensus target price of $89.75.
Get Our Latest Analysis on AZN
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
- Five stocks we like better than AstraZeneca
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- What is the FTSE 100 index?
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.